The author of the Patrick Melrose novels follows his career-long concern with the workings of the brain into an era of ...

Discover the charm of classic woodworking that can elevate any home to timeless elegance! 🏡✨ From intricate moldings to stunning built-ins, these features are the perfect blend of craftsmanship and ...

A longevity startup called Retro Biosciences is working on personalized blood disorder therapies thanks to a partnership with ...

Applied Therapeutics’ rare disease drug has failed another late-stage clinical trial, adding to the woes of a candidate that ...

Large amounts of data ("big data") offer enormous potential for improving the accuracy of genome-wide predictions in plant ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

With six newly established, identical BSL-2 laboratories now operational, biologics CDMO Northway Biotech can conduct VCS programs for up to six clients simultaneously, significantly alleviating ...

Puma Biotech (PBYI) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Shenzhen Genocury Biotech Co., Ltd. is a clinical-stage biotechnology pioneer redefining in vivo cell engineering through its proprietary Vivoexpress™ platform. This modular delivery system ...

The Samsung Galaxy Watch 8 Classic series seems a dead cert for a return in 2025, following its certification by the Bluetooth Special Interest Group. It’s hard enough to keep gadgets-in-waiting ...

Top business executives and industry experts convened Tuesday at the 2025 US Strategy Roundtable for Pharma and Biotech to assess Korea’s biotech standing at a critical juncture of global ...

China’s WuXi AppTec, which a US legislative commission called the “Huawei equivalent for biotechnology”, has reported a surge in US business despite increased scrutiny from Washington ...